PPI Prescriptions Research Articles

Validity and Execution of Stress Ulcer Prophylaxis in Surgical Patients: A Single-Center, Retrospective Cohort Analysis in Islamabad, Pakistan

Introduction: Stress ulcer prophylaxis (SUP) is recommended in critically ill patients to prevent stress-related mucosal damage, however, there is inconsistent adherence to established standards and guidelines for those who receive SUP medications outside of this patient group. The present study aimed to evaluate the appropriateness of SUP medications for surgical patients at the tertiary care hospital in Islamabad, Pakistan. Methodology: A 1-year, retrospective cohort study was conducted, using a convenience sampling approach, involving patients undergoing surgical procedures at the Surgical Wards of a tertiary care hospital located in Islamabad. Data collection was performed using a pre-designed checklist, with main areas including demographic characteristics, data on their presenting complaint, SUP medications (dosage, route of administration and duration) and presence of stress ulcer risk factors.Results: n=418 patient records were assessed: the majority of the patients were female (62.6%; n=262), with a mean age was 53.6±11.7 years, treated at the General Surgery department (81.8%; n=342). All patients managed for SUP were prescribed PPIs; the most commonly used PPI was omeprazole, both orally (37.7%; n=158) and parenterally (39.7%; n=166). The majority of patients (72.2%; n=302) were prescribed SUP for an appropriate indication or an associated risk. 46.1% (n=193) received SUP as a discharge medication with no records showing a follow-up, and there was no clear evidence that suggested that SUP had been stopped. Conclusions: This study highlights the irrational prescribing of PPIs in non-critical patients and the improper continuing of PPI prescriptions after discharge in a real-world setting, indicating the need to address suggested protocols for rationalizing the use of SUP and limiting the use of PPIs for appropriate purposes.

A262 THE EXCESS USE OF PROTON-PUMP INHIBITORS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE

Abstract Background Proton-pump inhibitors (PPI) use can impact the gut microbiome, thus, it is possible that use in children may be associated with an increase in pediatric IBD. Aims We investigated the common gastrointestinal symptoms that result in a PPI prescription in pediatrics prior to a diagnosis of IBD and the degree to which children with IBD use excess PPIs compared to controls either prior to or post a diagnosis of IBD. Methods The University of Manitoba IBD Epidemiology Database includes all Manitobans diagnosed with IBD 1984-2018 with age, sex, and geographic-matched controls. PPI prescription data were assessed from April 1995 onwards in children diagnosed with IBD prior to age 18. Results PPI were dispensed prior to IBD diagnosis in 9% of 614 children diagnosed with IBD and 0.8% of 5718 controls (P ampersand:003C0.0001) with the median age being 15 years. Children with Crohn’s disease were no more likely to have been PPI-users pre-diagnosis (10%) than persons with ulcerative colitis (8%, p=0.57). Relative PPI use increases within 1-year of an IBD diagnosis (rate ratio, RR=22.4 (95% CI 13.6-37); P ampersand:003C 0.001) compared with 3-5 years pre-IBD (RR=4.9, 95% CI 1.4-16.7) and 1-3-year pre-IBD (RR=2.5, 95% CI 1.01-6.2). The percent of children being prescribed a PPI increased the more they visited a physician, which was associated with increased likelihood of being prescribed a PPI. PPI use was similar for the various gastrointestinal diagnoses in cases of IBD and controls. PPI users prior to a diagnosis may have less severe disease than non-PPI users. We found they were less likely to be hospitalized (HR 0.36, 95% CI 0.19 – 0.68; P = 0.002). There was no difference among children who had surgery for their IBD whether they were PPI users prior to IBD diagnosis compared to non-users. Conclusions PPI use was commonly prescribed for a variety of gastrointestinal complaints, similarly in cases and controls. Children with IBD have many more contacts for gastrointestinal diagnoses than controls even for 5 years prior to their diagnosis. This raises the possibility that PPIs are prescribed indiscriminately for gastrointestinal complaints since their use was not restricted to complaints warranting PPI use, or that PPIs are prescribed for early symptoms that are secondary to IBD. Funding Agencies None

Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab.

Concomitant medications may alter the effect of biological therapy in inflammatory bowel disease. The aim was to investigate the effect of proton pump inhibitors on remission rates in patients with inflammatory bowel disease treated with the gut-selective vedolizumab. Patients from the Hungarian nationwide, multicenter vedolizumab cohort were selected for post hoc analysis. Primary outcomes were the assessment of clinical response and endoscopic and clinical remission at weeks 14 and 54. Secondary outcomes were the evaluation of the combined effect of concomitant steroid therapy and other factors, such as smoking, on remission. A total of 108 patients were identified with proton pump inhibitor data from 240 patients in the original cohort. Patients on steroids without proton pump inhibitors were more likely to have a clinical response at week 14 than patients on concomitant PPI (95% vs. 67%, p = 0.005). Non-smokers with IBD treated with VDZ were more likely to develop a clinical response at week 14 than smokers, particularly those not receiving PPI compared with patients on co-administered PPI therapy (81% vs. 53%, p = 0.041, and 92% vs. 74%, p = 0.029, respectively). We found that the use of PPIs in patients treated with VDZ may impair the achievement of response in certain subgroups. Unnecessary PPI prescriptions should be avoided.

Association of Proton Pump Inhibitor Use and Severe Pneumonitis in Stage III Non-Small-Cell Lung Cancer Treated with Primary Chemoradiation and Adjuvant Durvalumab

Prior studies have suggested gut microbiome changes induced by long-term acid-reducing medication use could modulate immunotherapy efficacy and toxicity. We assessed the relationship between baseline acid-reducing medication use (proton pump inhibitors [PPI] or H2 antagonists [H2A]) on treatment-related toxicity and efficacy in a large cohort of stage III non-small-cell lung cancer (NSCLC) patients treated with or without immunotherapy. Patients with unresectable stage III NSCLC treated with primary concurrent chemoradiation with or without adjuvant durvalumab from 2015 to 2021 were identified in the Veterans Affairs (VA) system. We defined baseline acid-reducing medication use with VA and non-VA pharmacy records in the year prior to radiation start; the number of prescriptions and the cumulative duration of therapy were quantified. Using multivariable Cox models adjusting for potential baseline confounders and stratified by adjuvant durvalumab use, we estimated the association between PPI or H2A use and subsequent severe pneumonitis, progression-free survival, and overall survival. Pneumonitis was determined and graded by manual chart review. We included 1994 patients with stage III NSCLC treated with primary chemoradiation, of whom 1005 (50%) received adjuvant durvalumab, 1064 (53%) received any PPI and 1030 (52%) received any H2A. In the overall sample, baseline use of any PPI was associated with increased risk of grade 3-5 pneumonitis (adjusted hazard ratio [aHR] 1.53, 95% CI 1.12-2.10, p = 0.008) and was found to be significant only in durvalumab-treated patients (aHR 1.67, 95% CI 1.10-2.54, p = 0.016), but not for patients treated without durvalumab (aHR 1.34, 95% CI 0.82-2.20, p = 0.2). Higher number of PPI prescriptions were associated with increased risk of severe pneumonitis (aHR 1.38 per 5 prescriptions, 95% CI 1.03-1.85, p = 0.03) and longer duration of PPIs trended toward significance (aHR 1.04 per 90 days, 95% CI 1.00-1.09, p = 0.066). Any PPI use was associated with worse OS in durvalumab-treated patients (aHR 1.30, 95% CI 1.05-1.61, p = 0.016) but not for patients without durvalumab use (aHR 0.99, 95% CI 0.86-1.14, p = 0.9). PPI use had no association with progression-free survival in either cohort. No significant associations between baseline H2A use and pneumonitis, PFS, or OS in either cohort were seen. PPIs, but not H2As, are associated with increased risk of treatment-related pneumonitis and inferior OS in stage III NSCLC patients treated with chemoradiation and immunotherapy. This association was not observed among patients treated with chemoradiation alone. No association was found between PPI use and cancer progression. Further work is warranted to confirm these findings in other immunotherapy-treated cohorts.

Using an algorithm to assess the rate and trend over time of inappropriate proton pump inhibitors prescription upon hospital discharge.

There is an increasing interest in inappropriate proton pump inhibitors prescription (InPPIp), as defined by the National Institute for Clinical Excellence (NICE) guidelines. To evaluate the rate, trend over time and factors associated with InPPIp upon discharge from internal medicine departments. We evaluated patients discharged from internal medicine departments with a PPI prescription in 2014 and 2017 at an academic referral center according to a developed algorithm. A total of 3,982 patients were included (50.8% women, 74% ≥ 65 years). The rate of InPPIp was 44.3% (95% CI 42.8-45.9) for the entire cohort; 68.1% for subjects aged < 65 years and 36.0% for those aged ≥ 65 years (p<0.001); 43.2% in 2014 and 45.6% in 2017 (p=0.130). In a decision-tree analysis, after the exclusion of 448 patients with gastrointestinal indications, 89.4% (1,580/1,766) of all InPPIp cases were of patients without dual antiplatelet treatment (DAPT) and 8.6% (151/1,766) were of patients younger than 65 years, who were taking aspirin. The rate of InPPIp is high, especially among patients not receiving DAPT and young patients taking aspirin. Time trend analysis showed no improvement over time. Our algorithm may serve as an automated quality measuring tool to reduce InPPIp.

A197 INVESTIGATING THE PROTON-PUMP INHIBITOR USE PRECEDING AND POST AN INFLAMMATORY BOWEL DISEASE DIAGNOSIS

Abstract Background Proton-pump inhibitors (PPI) have an impact on gut microbiome. The use of PPI has increased since the late 1980s and between 2007-2017, there were nearly 59 million PPIs dispensed annually in France.1 Considering that inflammatory bowel disease (IBD) affects persons of all races, a disease trigger for IBD may be a factor that can directly alter the intestinal immune response, or indirectly through changes in the gut microbiome. This raises the possibility that the advent use of PPI may be associated with the worldwide rise in IBD. Purpose We investigated whether increased use of PPI was associated with a diagnosis of IBD. Method The University of Manitoba IBD Epidemiology Database includes all Manitobans diagnosed with IBD between 1984 to 2018 with age, sex and geography-matched controls and comprehensive prescription drug data from April 1995. Subjects were considered to be users if they received 2 prescriptions of PPI. We assessed PPI prescriptions pre-diagnosis and for 3-years post-diagnosis of IBD. The absolute and relative rates were calculated and compared for PPI use pre- and post-IBD diagnosis. Result(s) A retrospective analysis was completed by analyzing 5920 subjects that were diagnosed with IBD after April 1996. Rates of PPI use in controls increased gradually from 1.5 to 6.5% over 15-years. Persons with IBD have a higher rate of PPI use peaking up to 17% within 1-year of IBD diagnosis with a rate ratio (RR) of 3.1 [95% CI 2.9 – 3.3]. Furthermore, persons with Crohn’s disease (CD) [RR= 4.2; 95% CI 3.7 – 4.6] were more likely to have been PPI users pre-diagnosis than persons with ulcerative colitis [RR= 2.4; 95% CI 2.2 – 2.7]. Important predictors of increased PPI use were older age, year of data collection and CD diagnosis. Conclusion(s) This retrospective analysis showed an increase in PPI use over the past 20-years among all Manitobans. Persons with IBD have higher PPI use within 1-year of their IBD diagnosis. It is possible that persons with IBD have an increase in acid peptic diseases or alternatively, the use of a PPI alters the gut microbiome increasing the risk for IBD diagnosis, or that some IBD symptoms are treated with PPI whether warranted or not. Future studies are needed to delineate whether the indication for ongoing PPI use is appropriate.

What is the significance of the Hill classification?

This study aimed to investigate the significance of Hill classification to predict esophagitis, Barrett's esophagus, gastroesophageal reflux disease (GERD) symptomatology, and future prescriptions of proton pump inhibitors in clinical practice. A total of 922 patients (546 women and 376 men; mean age 54.3 [SD 18.4] years) who underwent gastroscopy between 2012 and 2015 were analyzed. Patient questionnaire regarding symptoms were compared with endoscopy findings. A medical chart review was done that focused on the prescription of PPIs, additional gastroscopies, and GERD surgery in a 3-year period before the index gastroscopy and in a 6-year period afterward. In patients naïve to PPI prescriptions (n= 466), Hill grade III was significantly associated with esophagitis (AOR 2.20; 95% CI 1.00-4.84) and > 2 PPI prescriptions 6 year after the index gastroscopy (AOR 1.95; 95% CI 1.01-3.75), whereas Hill grade IV was significantly associated with esophagitis (AOR 4.41; 95% CI 1.92-10.1), with Barrett's esophagus (AOR 12.7; 95% CI 1.45-112), with reported heartburn (AOR 2.28; 95% CI 1.10-4.74), and with >2 PPI prescriptions (AOR 2.16; 95% CI 1.02-4.55). In patients 'non-naïve' to PPI prescription (n= 556), only Hill grade IV was significantly associated with esophagitis, reported heartburn, and with >2 PPI prescriptions. The gastroscopic classification in Hill grades III and IV is important in clinical practice because they are associated with esophagitis, Barrett's esophagus, symptoms of GERD, and prescriptions of PPIs, whereas a differentiation between Hill grades I and II is not.

Optimizing Endoscopy Procedure Documentation Improves Guideline-Adherent Care in Upper Gastrointestinal Bleeding

Background and AimsUpper GI bleeding (UGIB) is a common indication for inpatient esophagogastroduodenoscopy (EGD). Guideline adherence improves post-EGD care, including appropriate medication dosing/duration and follow-up procedures that reduce UGIB-related morbidity. We aimed to optimize and standardize post-EGD documentation to improve process and clinical outcomes in UGIB-related care.MethodsWe performed a prospective quality improvement study of inpatient UGIB endoscopies at an academic tertiary referral center during 6/2019–7/2021. Guidelines were used to develop etiology/severity-specific electronic health record note templates. Participants (39 faculty/15 trainees) completed 10-min training in template content/use. We collected pre/post-intervention process data on “Minimal Standard Report” (MSR) documentation including patient disposition, diet, and medications. We also recorded documentation of re-bleed precautions and follow-up procedures. Study outcomes included guideline-based medication prescriptions, ordering of follow-up EGD, and post-discharge re-bleeding. Pre/post-intervention analysis was performed using chi-square tests.ResultsFrom a pre-intervention baseline of 199 patients to 459 patients post-intervention, compliance improved with inpatient PPI (53.4–77.9%, p < 0.001) and discharge PPI (31.3–61.0%, p < 0.001) prescriptions. There was improvement in MSR completion (28.6–42.5%, p < 0.001). Compliance improved with octreotide prescriptions (75.0–93.6%, p = 0.002) and follow-up EGD order (61.3–87.1%, p < 0.001). There was no change in post-discharge re-bleeding. 82.6% of cases used templates.ConclusionsOur project leveraged endoscopy software to standardize documentation, resulting in improved clinical care behavior and efficiency. Our intervention required low burden of maintenance, and sustainability with high utilization over 9 months. Similar endoscopy templates can be applied to other health systems and procedures to improve care.

Appropriateness of proton pump inhibitors prescription in patient admitted to hospital: An observational study

The objective of this study was to assess the relevance of proton pump inhibitors prescribing in patients entering a ward with a clinical pharmacist and therefore identifying inappropriate prescribing. A prospective study was conducted for 4 months. Patients admitted to the hospital for elective or emergency surgery, who had medication reconciliation performed by the clinical pharmacy team and who were prescribed proton pump inhibitors before admission were included. The indication for the proton pump inhibitors was collected from the patient or inferred from the medical history. The compliance of the prescriptions with the marketing authorization indications and the duration of treatment and dose was analyzed. The indications were classified into 3 groups: compliant with marketing authorization, off label but relevant use, and strictly off label use. During the study period, 100 patients were included among whom only 29% had a PPI prescription that did fully comply with the recommendations. Among the twenty-three prescriptions that did not comply with the recommendations in terms of indication, 15 were not relevant at all. Among the 65 prescriptions relevant for indication, 36 were not compliant with dose or duration recommendations. 59% of the total number of patients reported that they had never tried to stop treatment. Our study highlights the need for regular reassessment of proton pump inhibitors prescriptions. Multi-disciplinary collaboration on the appropriate use of this class of medication as well as increased awareness among general practitioners and hospital doctors is essential.

S1496 Addressing over Prescription of PPI in an Outpatient Underserved Population

Introduction: Long term use of PPIs has been associated with increased risk of mineral and vitamin deficiencies and in some studies with C. Difficile Colitis. It is estimated that 25%-70% of PPI prescriptions are without an appropriate indication. The aim of this study was to discontinue at least 10% of the patients on PPIs who do not have an appropriate indication for therapy over the course of a 6-week period. Methods: This study took place at a medically underserved resident clinic in Hartford Connecticut. Patients scheduled between 09/16/21 and 10/01/21 were pre-screened using EMR review. Any patient with a PPI on their medication list was included in the data set. Patients were stratified based on clinical need for PPI and potential for tapering using ACG Clinical Guidelines. Providers were educated on the clinical guidelines for PPI therapy. Patients on standard dosing were reduced to 50% dosing for 2 weeks and then discontinued. Patients were provided with as needed H2 Blocker for possible rebound symptoms. A total of 114 patients on PPI with appointments during the time window were identified. On the date of their visit, providers assessed individual patient PPI usage and discontinuation eligibility. Patients eligible for discontinuation of PPI were advised to dose reduce by 50% for 2 weeks and prescribed as needed H2 blocker. Providers also provided education on how to take PPI appropriately. Patients were called 2 weeks later for follow up. At that time if symptoms tolerated, PPI was discontinued. Results: Of the total population, 28% (32/114) were on long term PPI appropriately. Seventy-two percent (82/114) of the patients prescribed PPI lacked a true medical indication. Of these, 44 patients were seen and provided a taper plan. PPI was discontinued successfully in 22% (18/82) of the population of inappropriately prescribed PPI within the 6-week window. Conclusion: The aim of this study to achieve 10% population reduction in inappropriate PPI use was exceeded with roughly 22% discontinuation. Frequent medication reconciliation, patient education on proper PPI use and physician education with ACG Clinical Guidelines were simple changes to successfully improve clinically indicated PPI therapy. Many patients are aware of their triggers and use PPIs as a means of avoiding lifestyle and dietary change. When prescribing PPI, placing a “stop” time on the prescription may further reduce PPI burden.

Anemia in nursing homes, proton pump inhibitors and prescribing cascade of antianemic drugs.

Some medications can cause anemia through their effect on gastrointestinal function, such as proton pump inhibitors and H2-antagonists, and on the risk of bleeding, such as anticoagulants and antiplatelet agents. The main aim of this study is to evaluate how anemia is related with the most commonly used drugs in a large sample of NH residents. This retrospective cross-sectional multicenter study was conducted in a sample of Italian long-term care NHs distributed throughout the country. In all, 2602 NH residents recruited from 27 Italian long-term NHs (mean age ± SD: 88.4 ± 8.5) and 441 (16.9%) had a diagnosis of anemia. The unadjusted model showed a significant relation with PPI (OR 1.71, 95% CI 1.39-2.11, p < 0.0001). This relation was maintained in the model adjusted for age, sex, CKD, atrophic gastritis, peptic ulcer and rheumatic disease (OR 1.61, 95% CI 1.31-1.99, p < 0.0001). PPI users were also at higher risk of being treated with antianemicdrugs-iron supplements, folate, vitamin B12 and erythropoietin (OR 2.03, 95% CI 1.67-2.48, p < 0.0001)-even if they did not have anemia (OR 1.94, 95% CI 1.55-2.42, p < 0.0001). Proton pump inhibitors are associated with anemia in NH residents. PPIs are also related with an increased probability of receiving drugs to treat anemia, such as iron supplements, folate or cyanocobalamin and erythropoietin, as the effect of a prescribing cascade. Optimization of PPI prescription is needed to avoid adverse events and promote rational drug prescription.

Prescripción potencialmente inapropiada en adultos mayores en México

ABSTRACTOBJECTIVE To identify and quantify potentially inappropriate prescribing (prescripción potencialmente inapropiada, PPI) and other drug prescribing problems in public health care services in a population-based study at the three existing levels of complexity in Mexico.METHODS Descriptive analysis of the Study on Satisfaction of Users of the Social Protection System in Health 2014–2016, prescription and drug supply section, to obtain the prevalence of PPI in older adults (≥ 65 years), based on Beers, STOPP, Prescrire and BSP listings using AM (older adults) prescription indicators, one for each listing.RESULTS Most older adults (67%) were prescribed at least one medication, with a mean of 2.7 medications per prescription. The PPI prevalence was 74% according to the BSP criteria, 67% according to the STOPP listing, 59% with the Beer criteria, and 20% with Prescrire. The most frequent PPI prescriptions were NSAIDs, vasodilators and sulfonylureas.CONCLUSIONS The use of PPIs in AM is high in Mexico. The higher prevalence found in this study may reflect the use of a source with population representativeness. The partial use and adaptations of the criteria make difficult comparing the studies; however, the STOPP criteria are the ones with the highest prevalence, as they cover a greater number of drugs and their use is more common in the first level of care.

1268 Pathology Pick up Rate in Routine Preoperative Endoscopy and its Impact on Patients Undergoing Gastric Bypass Surgery

Abstract Aim Preoperative OGD in patients undergoing bariatric surgery, has been a subject for debate for decades. The aim of this study is to evaluate the pathology pick up rate in routine preoperative endoscopy in patients undergoing Gastric Bypass surgery (LRYGB) in our unit. Method Retrospective review of patients’ records who underwent LRYBG in our unit from February 2009 to March 2020. Patients were divided into two groups according to the presence or absence of symptoms prior to bariatric surgery: Group A (Asymptomatic) and Group B (Symptomatic). Data from prospectively kept electronic OGD reports, CLO test results, histology reports and the changes in management plan were collected and analysed. Results 114 patients were included in the analysis, 85 (74.56%) were in group A and 29 in group B. OGD detected pathology in 34 patients in group A and 21 in group B (p = 0.004). Those included hiatus hernia (HH) (17.65% group A, 44.83% group B, p = 0.006); stomach ulcer (7.06% group A, 3.45% group B, p = 0.676), H.pylori infection (12.86% group A, 29.41% group B). This led to change of management in 22 patients in group A and 12 of group B (p = 0.157) excluding PPI prescription. Those changes included H.pylori eradication (10.59% group A, 17.24% group B, p = 0.153), HH repair (3.53% group A, 24.14% group B, p = 0.002). There was no cancellation or change in bariatric surgery offered in both groups. Conclusions Preoperative OGD has only significantly impacted the bariatric patient’s pathway in symptomatic patients. However, in Asymptomatic patients, OGD could be replaced by cheaper and non-invasive alternatives.

66 The Use of Proton Pump Inhibitors in An Older Population in A Tertiary Hospital: A Patient Safety Issue?

Abstract Background PPIs form part of the most commonly prescribed medications in Ireland. There has been emerging concern regarding the risks associated with their chronic use. PPI use has been linked with clostridium difficile infection, pneumonia, hypomagnesaemia, nephrotoxicity, hyponatraemia as well as many other GI and non GI pathologies including dementia. Therefore there has been emerging concern regarding their chronic use. The aim of our audit was to identify the spot prevalence and appropriateness of PPI use for gastro-protection in an older population of medical inpatients in accordance with NICE 2014 PPI guidance “Management of dyspepsia in adults in primary care.” Methods We audited the prevalence of PPI use in medically admitted patients aged ≥65 years at our institution and the use of PPIs within this population. Patients' admission proforma, clinical notes, and drug kardex were reviewed. We collected: age, gender, past medical history, drug list, and laboratory results. This data was used to identify the prevalence and appropriateness of PPI use. Results The total number of medically admitted patients aged ≥65 years was 107. 52(48.5%) were prescribed PPIs. Of the 52, only 7(13.4%) had an appropriate indication: Five patients had concomitant prescription of low dose Aspirin ± clopidogrel and a documented history of gastritis/esophagitis/duodenitis. One patient had a hiatus hernia and gastro-esophageal reflux disease. One patient had chronic NSAID use due to arthritis. Subgroup analysis showed 46/52 were prescribed high dose PPI without indication. Conclusions Our audit confirms this showing that almost 50% of patients aged ≥ 65y admitted to our hospital have been prescribed PPIs. Furthermore, PPI prescriptions were only appropriate in 13.4%. In line with recent guidelines, NICE PPI guidance 2014 and AGA Best Practice Guidelines, our data shows there is scope to rationalise PPI use in older people with resultant cost savings and reduction in complications.

608 Prevalence of Acid Suppressive Prophylaxis in Hospitalized Patients for Peptic Ulcer Disease and Complications: Retrospective Study

INTRODUCTION: An NSAID is present in about 8% of all prescriptions written by primary care physicians. Among GI-related adverse drug events, 23.5% were related to NSAIDs, 45% were considered avoidable. Risk factors associated with peptic ulcer disease include: History of peptic ulcer or ulcer bleeding, positive status of H Pylori, age (&gt;65 years), Concomitant use of warfarin, steroids, anti-platelets. Study in France, showed that gastroprotection was not prescribed in 16% of patients on NSAIDs and risk factors for GI toxicity. Misoprostol and PPI therapy are proved to reduce the risk of GI toxicity. Current guidelines recommend that high risk patients should be prescribed COX2 selective agents by itself or non-selective agents with gastroprotection. METHODS: We performed a retrospective chart review of patients at Truman Medical Center Hospital Hill, Missouri who were hospitalized for NSAID-related peptic ulcer disease from the time period of January 2013 till September 2018. We further included only patients with risk factors of peptic ulcer disease and should have been on gastroprotective agents prior to presentation. RESULTS: Our sample included 81 patients hospitalized for NSAID-related peptic disease with risk factors for peptic ulcer disease. Mean age was 58.2 years old. More than half of patients were male (56.8%). Around 47% were smokers and 41% were alcohol current users. Around third of patients were taking aspirin daily and only 13% were on anticoagulation. More than half of patient had History of peptic ulcer (52%) and 38% had history of bleeding ulcer. Only 44.4% of our patients were on gastroprotective agents prior to presentation. Significant portion of our sample presented with ulcer complication (i.e., bleeding, perforation) at 74.1% (60/81). About 60% of patient were anemic at presentation. 31% of patients presented with significant bleeding requiring more than 2 units of packed RBC. Gastroprotective agent prescription prior to presentation was significantly associated with aspirin use (P-value 0.038), anticoagulation (P-value 0.023), Hx coronary artery disease (P-value 0.023), history of peptic ulcer in the past (P-value 0.002) and anemia (P-value 0.003). CONCLUSION: Significant portion of patients who were hospitalized with peptic ulcer disease complications were not on gastroprotective agents although indicated. Risk stratification and PPI prescription when appropriate should be implemented more aggressively in outpatient setting.

458 – Successful Reduction of Overall and Inappropriate Ppi Prescriptions in a Primary Care Clinic

458 – Successful Reduction of Overall and Inappropriate Ppi Prescriptions in a Primary Care Clinic

1857P - Tyrosine kinase inhibitors and acid-inhibitory drugs: Strong concomitant dispensing and drug-drug interaction risk

Background: Tyrosine Kinase Inhibitors (TKIs) have rapidly become an established therapy in oncology and have been shown to be effective in a wide variety of solid and hematologic malignancies. Acid-inhibitory drugs (AID) (such as antacids, anti-ulcerous drugs and proton pump inhibitors - PPIs) increase the intragastric pH, which may subsequently decrease TKI solubility, bioavailability, and treatment efficacy. The Observatory of Drugs Bretagne/ Pays de la Loire (B-PL) and the Medical Department of the French Regional Health Insurance (FRHI PL) has made an observational study about TKIs and AIDs concomitant dispensing. Methods: FRHI has made an extract in its database for patients treated with TKIs and AIDs in 2016. Concomitant dispensing is defined as the dispensing of a TKI and AIDs during the same calendar month. To complete the study, a survey about PPIs prescription has been proposed to cancer specialists from B and PL areas during 15 days last December. Results: 2309 patients, mean age of 62.9 y (2-93) have been treated with TKIs in 2016 in the PL area. 6.6 dispensings have been done per patient. 795 pts (34%) had no AID dispensing. 274 pts (12%) had no concomitant dispensing of AID and TKI. 1240 pts (54%) had at least one concomitant dispensing. 67% of these patients had a concomitant dispensing of PPIs and 25% a concomitant prescription throughout the TKI treatment. Among these concomitant takes, 34% showed no interaction, 23% showed interactions (34% unknown cases, 9% diverging data). Data from the Bretagne area will be shown at the meeting. 43 clinicians have answered the survey about PPI prescription: 98% have prescribed them. The major reasons were: treatment of gastroesophageal reflux disease (88%), prevention/treatment of NSAID-associated ulcers (67%) or of esophageal duodenal and stomach ulcers (55%), for unknown reasons (31%), and for Zollinger-Ellison syndrome (31%). Duration of treatment was between 7 days and 2 months. Conclusions: Drug-Drug Interaction (DDI) analyses would be performed to underline for which TKIs, TKIs-PPIs interaction was the most harmful. Clear practice tools should be created to help clinicians to evaluate this DDI and what to do for their patients. Guidelines will be presented at the meeting. Legal entity responsible for the study: Cancer Observatory, OMEDIT B and PL. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

How do Swiss general practitioners agree with and report adhering to a top-five list of unnecessary tests and treatments? Results of a cross-sectional survey

Background: In 2014, the ‘Smarter Medicine’ campaign released a top five list of unnecessary tests and treatments in Swiss primary care, such as imaging for acute low-back pain and long-term prescribing of proton pump inhibitors.Objectives: Measure general practitioners’ (GPs) agreement with the recommendations and self-reported adherence.Methods: Cross-sectional, online survey of GPs in the ‘Swiss primary care active monitoring’ (SPAM) network, which assessed awareness of ‘Smarter Medicine’ and views on each recommendation. Questions included whether the clinical situation is common, whether the recommendation is followed, whether GPs agree with the recommendation and reasons why the recommendation would not be followed.Results: One-hundred-and-sixty-seven of 277 GPs from the SPAM network participated (60%), of which 104 (62%) knew of ‘Smarter Medicine’, including 79% in German areas, 49% in French areas and 38% in Italian areas (P < 0.001). Agreement with the five recommendations was high, with scores around nine out of 10. The proportion saying they typically follow each recommendation was 68 to 74%, except not continuing long-term PPI prescriptions without attempting dose reduction, with only 34%. Common reasons for not following the recommendations were patient or other provider requests and situations that might suggest the need for more aggressive care.Conclusion: Two years after the launch of the campaign, awareness and acceptance of ‘Smarter Medicine’ appear to be high among Swiss GPs. By self-report, the recommendations are adhered to by most of the respondents but there may be room for improvement, especially for long-term PPI prescriptions.

Sa1012 - Reducing PPI and H2RA Prescriptions in Pediatrics

Sa1012 - Reducing PPI and H2RA Prescriptions in Pediatrics

Use of proton pump inhibitors in general practice.

AIMTo evaluate the characteristics of the prescription of the proton pump inhibitor drugs (PPI) and the adherence to the indications of the guidelines regulating the reimbursement limitations set forth by the Italian Drug Agency.METHODSThirty general practitioners (GP) participated in the study, providing data on more than 40000 patients in total. The population was divided into non occasional users of PPI drugs (PPI users) and non-users (PPI non-users) based on evidence of a prescription of at least 3 packs of PPIs in the last 90 d before analysis. The data provided allowed an assessment of compliance with the requirements of eligibility for PPI reimbursement according to the Italian Drug Agency rules, in order to obtain subpopulations which complied or not with the rules.RESULTSSix thousand three hundred and twenty-two patients were found to be PPI users, accounting for 14.9% of the patient population. PPI users were more frequently female, older and more frequently diagnosed with gastroesophageal reflux disease, gastric or duodenal ulcers, arthropathy, heart disease and cancer than the rest of the population. PPI users had more frequently received prescriptions for non-steroidal ant-inflammatory drugs (NSAIDS), acetylsalicylic acid (ASA), oral anticoagulant therapy (OAT) and systemic steroids. PPI reimbursement resulted applicable to 69.3% of the PPI users, but a potential for reimbursement of PPI prescriptions was identified in the non PPI users for the treatment of peptic or reflux disease (8.5%) and for the protection of gastric damage caused by NSAIDS (6.1%). Patients who are potentially eligible for reimbursement are older, diagnosed with arthropathy and heart disease more frequently and most commonly receive NSAID and ASA prescriptions compared with PPI users who do not satisfy eligibility requirements. Patients in whom it was not possible to identify conditions related to prescription suitability were more frequently associated with use of OAT.CONCLUSIONA substantial number of patients who apparently do not meet prescription suitability conditions can be identified, but among non PPI users on the contrary, it is possible to identify an equal number of patients for whom prescription would be suitable. Poor suitability can be identified in the population receiving OAT. Thus, there is scope for decreasing inappropriate use of PPI drugs by adhering to certain criteria and by involving all interested parties.